Published in Lancet on February 27, 1999
What do we feed to food-production animals? A review of animal feed ingredients and their potential impacts on human health. Environ Health Perspect (2007) 1.52
Molecular epidemiology of vancomycin-resistant Enterococcus faecium in a large urban hospital over a 5-year period. J Clin Microbiol (1999) 0.81
Characterization of antibiotic resistance in commensal bacteria from an aquaculture ecosystem. Front Microbiol (2015) 0.81
Vancomycin-resistant Enterococcus faecium strains isolated from community wastewater from a semiclosed agri-food system in Texas. Antimicrob Agents Chemother (2005) 0.79
An Update on the Emergence of Glycopeptide Resistance in Enterococci. Curr Infect Dis Rep (1999) 0.77
Resistance to vancomycin in US chicken feed. Lancet (1999) 0.77
Contamination of animal feed by multiresistant enterococci. Lancet (1999) 0.76
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
Cholera. Clin Microbiol Rev (1995) 12.33
Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med (1987) 7.82
Factors associated with mortality in feedlot cattle: the Bruce County Beef Cattle Project. Can J Comp Med (1980) 7.74
Cholera and other vibrioses in the United States. N Engl J Med (1985) 5.17
Bacteriophage therapy. Antimicrob Agents Chemother (2001) 5.16
Oxygen and the growth and metabolism of Clostridium acetobutylicum. J Gen Microbiol (1971) 4.91
A Vibrio cholerae pathogenicity island associated with epidemic and pandemic strains. Proc Natl Acad Sci U S A (1998) 4.75
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect Immun (1988) 4.44
Factors associated with mortality and treatment costs in feedlot calves: the Bruce County Beef Project, years 1978, 1979, 1980. Can J Comp Med (1982) 4.34
Factors associated with morbidity and mortality in feedlot calves: the Bruce County beef project, year two. Can J Comp Med (1981) 4.17
Emerging foodborne pathogens: Escherichia coli O157:H7 as a model of entry of a new pathogen into the food supply of the developed world. Epidemiol Rev (1996) 4.09
A bacteriophage encoding a pathogenicity island, a type-IV pilus and a phage receptor in cholera bacteria. Nature (1999) 3.89
Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med (1995) 3.77
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther (2011) 3.53
Harlequin syndrome: the sudden onset of unilateral flushing and sweating. J Neurol Neurosurg Psychiatry (1988) 3.47
Phenotypic evaluation of acapsular transposon mutants of Vibrio vulnificus. Infect Immun (1990) 3.47
Non-O group 1 Vibrio cholerae gastroenteritis in the United States: clinical, epidemiologic, and laboratory characteristics of sporadic cases. Ann Intern Med (1981) 3.25
Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med (1995) 3.11
Learning and memory difficulties after environmental exposure to waterways containing toxin-producing Pfiesteria or Pfiesteria-like dinoflagellates. Lancet (1998) 3.03
Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J Clin Invest (1987) 3.03
A new route of transmission for Escherichia coli: infection from dry fermented salami. Am J Public Health (1996) 2.78
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther (2013) 2.73
Vibrio cholerae O139 synonym bengal is closely related to Vibrio cholerae El Tor but has important differences. Infect Immun (1994) 2.73
In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob Agents Chemother (1996) 2.63
Evaluation of DNA colony hybridization and other techniques for detection of virulence in Yersinia species. J Clin Microbiol (1989) 2.58
Production of Solvents by Clostridium acetobutylicum Cultures Maintained at Neutral pH. Appl Environ Microbiol (1984) 2.51
Back pain: a randomized clinical trial of rotational manipulation of the trunk. Br J Ind Med (1974) 2.47
Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains. Infect Immun (1995) 2.45
Cloning of the cytotoxin-hemolysin gene of Vibrio vulnificus. Infect Immun (1985) 2.42
Stool microflora in extremely low birthweight infants. Arch Dis Child Fetal Neonatal Ed (1999) 2.41
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
On the permeability to weak acids and bases of the cytoplasmic membrane of Clostridium pasteurianum. Biochem Biophys Res Commun (1981) 2.32
Visceral fat and race-dependent health risks in obese nondiabetic premenopausal women. Diabetes (1997) 2.26
The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1. Infect Immun (1995) 2.25
Practice-based research: lessons from community pharmacist participants. Pharmacotherapy (2001) 2.23
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Vibrio cholerae O1 can assume a chlorine-resistant rugose survival form that is virulent for humans. J Infect Dis (1996) 2.17
Illness caused by Vibrio damsela and Vibrio hollisae. Lancet (1982) 2.17
Distribution of Vibrio vulnificus in the Chesapeake Bay. Appl Environ Microbiol (1996) 2.10
The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry (1999) 2.07
Non-O:1 Vibrio cholerae bacteremia: case report and review. Rev Infect Dis (1988) 2.07
Eu oxidation state in fluorozirconate-based glass ceramics. J Appl Phys (2009) 2.06
Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab (2012) 2.06
Half-time and high-speed running in the second half of soccer. Int J Sports Med (2012) 2.03
A research-based guideline for appropriate use of transdermal fentanyl to treat chronic pain. Oncol Nurs Forum (1998) 2.03
Characterization of Salmonella enterica serotype newport isolated from humans and food animals. J Clin Microbiol (2003) 2.02
Cloning and sequence of a region encoding a surface polysaccharide of Vibrio cholerae O139 and characterization of the insertion site in the chromosome of Vibrio cholerae O1. Mol Microbiol (1996) 2.01
Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood (1995) 1.99
Comparison of DNA probes and the Sereny test for identification of invasive Shigella and Escherichia coli strains. J Clin Microbiol (1986) 1.96
Activation of the antioxidant response element in primary cortical neuronal cultures derived from transgenic reporter mice. J Neurochem (2002) 1.96
The McGurk effect in infants. Percept Psychophys (1997) 1.96
Utilization of L-threonine by a species of Arthrobacter. A novel catabolic role for "aminoacetone synthase". Biochem J (1969) 1.95
Thermal conductivity spectroscopy technique to measure phonon mean free paths. Phys Rev Lett (2011) 1.94
Rapid identification of Vibrio vulnificus on nonselective media with an alkaline phosphatase-labeled oligonucleotide probe. Appl Environ Microbiol (1993) 1.94
Identification of environmental Vibrio vulnificus isolates with a DNA probe for the cytotoxin-hemolysin gene. Appl Environ Microbiol (1987) 1.94
Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther (1999) 1.93
Accuracy of an electromagnetic tracking device: a study of the optimal range and metal interference. J Biomech (1996) 1.89
Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.88
The extracellular cytolysin of Vibrio vulnificus: inactivation and relationship to virulence in mice. Infect Immun (1991) 1.87
Non-O1 Vibrio cholerae NRT36S produces a polysaccharide capsule that determines colony morphology, serum resistance, and virulence in mice. Infect Immun (1992) 1.86
Superoxide dismutase in some obligately anaerobic bacteria. FEBS Lett (1975) 1.85
Characterization of Neisseria gonorrhoeae protein II phase variation by use of monoclonal antibodies. Infect Immun (1984) 1.83
Purification and determination of the structure of capsular polysaccharide of Vibrio vulnificus M06-24. J Bacteriol (1992) 1.81
The cytolysin gene of Vibrio vulnificus: sequence and relationship to the Vibrio cholerae E1 Tor hemolysin gene. Infect Immun (1990) 1.79
Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia (2010) 1.76
Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers. J Infect Dis (1995) 1.75
Relapsing invasive group B streptococcal infection in adults. Ann Intern Med (1995) 1.74
Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells. J Biol Chem (2001) 1.74
Facial sweating in Horner's syndrome. Brain (1984) 1.73
Investigation of an outbreak of Salmonella enteritidis gastroenteritis associated with consumption of eggs in a restaurant chain in Maryland. Am J Epidemiol (1988) 1.71
Development and testing of a nonradioactive DNA oligonucleotide probe that is specific for Vibrio cholerae cholera toxin. J Clin Microbiol (1992) 1.71
Molecular techniques in the study of Salmonella typhi in epidemiologic studies in endemic areas: comparison with Vi phage typing. Am J Trop Med Hyg (1986) 1.68
Seroprevalence of Helicobacter pylori in Seventh-Day Adventists and other groups in Maryland. Lack of association with diet. Arch Intern Med (1990) 1.68
Self-efficacy, psychosocial factors, and exercise behavior in traditional versus modified cardiac rehabilitation. J Cardiopulm Rehabil (2001) 1.67
Thoracoscopic neodymium: yttrium-aluminum garnet laser-assisted pulmonary resection. Ann Thorac Surg (1991) 1.67
Improved pulsed-field gel electrophoresis for typing vancomycin-resistant enterococci. J Clin Microbiol (2000) 1.66
A radioactive antigen-binding assay for the measurement of antibody to Haemophilus influenzae type b capsular polysaccharide. J Immunol Methods (1981) 1.65
Measuring quality of life in paediatric patients. Pharmacoeconomics (1999) 1.65
Cholera in Lima, Peru, correlates with prior isolation of Vibrio cholerae from the environment. Am J Epidemiol (1997) 1.65
Vibrio metschnikovii bacteremia in a patient with cholecystitis. J Clin Microbiol (1981) 1.65
Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet (2001) 1.64
Cellular and humoral immune response of foals to vaccination with Corynebacterium equi. Can J Comp Med (1979) 1.64
The oxidation state of europium in halide glasses. J Phys Condens Matter (2011) 1.62
Seroprevalence of Helicobacter pylori in Chile: vegetables may serve as one route of transmission. J Infect Dis (1993) 1.59
Identification of a group 1-like capsular polysaccharide operon for Vibrio vulnificus. Infect Immun (2001) 1.58
Effect of metronidazole on hydrogen production by Clostridium acetobutylicum. Arch Mikrobiol (1972) 1.57
Cross-sectional validity of a modified Edmonton symptom assessment system in dialysis patients: a simple assessment of symptom burden. Kidney Int (2006) 1.56
Spo0A directly controls the switch from acid to solvent production in solvent-forming clostridia. Mol Microbiol (2000) 1.55
Dandy-Walker malformation: etiologic heterogeneity and empiric recurrence risks. Clin Genet (1985) 1.52